Elevated expression of LSD1 (Lysine-specific demethylase 1) during tumour progression from pre-invasive to invasive ductal carcinoma of the breast

BMC Clinical Pathology

Reinhard Buettner¹  Jutta Kirfel³  Henning Lorenzen²  Susanne Steiner³  Annette Gnatzy³  Nuran Serce³ 

[1] Institute of Pathology, University of Cologne, Kerpener Str. 62, Cologne, 50924, Germany;Institute of Medical Biometrics, Informatics and Epidemiology, University of Bonn, Sigmund-Freud-Str. 25, Bonn 53127, Germany;Institute of Pathology, University of Bonn, Sigmund-Freud-Str. 25, Bonn 53127, Germany

关键词: IDC;    DCIS;    LSD1;   

Others  :  1085352
DOI  :  10.1186/1472-6890-12-13

 received in 2012-02-13, accepted in 2012-08-13,  发布年份 2012

【 摘 要 】

Background

Lysine-specific demethylase1 (LSD1) is a nuclear protein which belongs to the aminooxidase-enzymes playing an important role in controlling gene expression. It has also been found highly expressed in several human malignancies including breast carcinoma. Our aim was to detect LSD1 expression also in pre-invasive neoplasias of the breast. In the current study we therefore analysed LSD1 protein expression in ductal carcinoma in situ (DCIS) in comparison to invasive ductal breast cancer (IDC).

Methods

Using immunohistochemistry we systematically analysed LSD1 expression in low grade DCIS (n = 27), intermediate grade DCIS (n = 30), high grade DCIS (n = 31) and in invasive ductal breast cancer (n = 32). SPSS version 18.0 was used for statistical analysis.

Results

LSD1 was differentially expressed in DCIS and invasive ductal breast cancer. Interestingly, LSD1 was significantly overexpressed in high grade DCIS versus low grade DCIS. Differences in LSD1 expression levels were also statistically significant between low/intermediate DCIS and invasive ductal breast carcinoma.

Conclusions

LSD1 is also expressed in pre-invasive neoplasias of the breast. Additionally, there is a gradual increase of LSD1 expression within tumour progression from pre-invasive DCIS to invasive ductal breast carcinoma. Therefore upregulation of LSD1 may be an early tumour promoting event.

【 授权许可】

   
2012 Serce et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Culhane JC, Cole P: LSD1 and the chemistry of histone demethylation. Chem Bio 2007, 11:561-568.
• [2]Strahl BD, Allis CD: The language of covalent histone modification. Nature 2000, 403:41-45.
• [3]Lan F, Nottke AC, Shi Y: Mechanisms involved in the regulation of histone lysine demethylases. Curr Opin Cell Biol 2008, 20(3):316-325.
• [4]Shi YJ, Matson C, Lan F, Iwase S, Baba T, Shi Y: Regulation of LSD1 histone demethylase activity by associated factors. Mol Cell 2005, 19:857-864.
• [5]Forneris F, Battaglioni E, Mattevi A, Binda C: New roles of flavoproteins in molecular cell biology: Histone demethylase LSD1 and chromatin. FEBS 2009, 276:4304-4312.
• [6]Scoumanne A, Chen X: The lysine-specific demethylase 1 is required for cell proliferation in both p53-depended and –independend manners. J Biol Chem 2007, 282:15471-15478.
• [7]Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA, Shi Y: Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004, 119:941-953.
• [8]Metzger E, Imhof A, Patel D, Kahl P, Hoffmeyer K, Friedrichs N, Müller JM, Greschik H, Kirfel J, Ji S, Kunowska N, Beisenherz-Huss C, Günther T, Buettner R, Schüle R: Phosphorylation of histone H3T6 by PKCßI controls demethylation at histone H3K4. Nature 2010, 464:792-796.
• [9]Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R, Solleder G, Bastian PJ, Ellinger J, Metzger E, Schüle R, Buettner R: Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res 2006, 66(23):11341-11347.
• [10]Schulte JH, Lim S, Schramm A, Friedrichs N, Koster J, Versteeg R, Ora I, Pajtler K, Klein-Hitpass L, Kuhfittig-Kulle S, Metzger E, Schüle R, Eggert A, Buettner R, Kirfel J, et al.: Lysine-specific demethylase 1 is strongly expressed in poor differentiated neuroblastoma: implications for therapy. Cancer Res 2009, 69:2065-2071.
• [11]Hayami S, Kelly JD, Cho HS, Yoshimatsu M, Unoki M, Tsunoda T, Field HI, Neal DE, Yamaue H, Ponder BA, Nakamura Y, Hamamoto R: Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. International Journal of Cancer 2011, 128(3):574-586.
• [12]Kauffmann EC, Robinson BD, Downes MJ, Powell LG, Lee MM, Scherr DS, Gudas LJ, Mongan NP: Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localilzed and advanced human bladder cancer. Mol Carcinog 2011, 50(12):931-944.
• [13]Lim S, Janzer A, Becker A, Zimmer A, Schüle R, Buettner R, Kirfel J: Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis 2010, 31(3):512-520.
• [14]Cui X, Schiff R, Arpino G, Osborne CK, Lee AV: Biology of progesterone receptor loss in breast cancer and its implication for endocrine therapy. J Clin Oncol 2005, 23(30):7721-7735.
• [15]Bradley C, van der Meer R, Roodi N, Yan H, Chandrasekharan MB, Sun ZW, Mernaugh RL, Parl FF: Carcinogen-induced alteration in normal human mammary epithelial cells. Carcinogenesis 2007, 28(10):2184-2192.
• [16]Tavassoli FA, Devilee P: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press, Lyon; 2003.
• [17]Remmele W, Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunhistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987, 8(3):138-140.
• [18]Punglia RS, Burstein HJ, Weeks JC: Radiation therapy for ductal carcinoma in situ: a decision analysis. Cancer 2012, 118(3):603-611.
• [19]Boughey JC, Gonzalez RJ, Bonner E, Kuerer HM: Current treatment and clinical trial developments for ductal carcinoma in situ of the breast. Oncologist 2007, 12(11):1276-1287.
• [20]Kuerer HM, Buzdar AU, Mittendorf EA, Esteva FJ, Lucci A, Vence LM, Radvanyi L, Meric-Bernstam F, Hunt KK, Symmans WF: Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer 2011, 117(1):39-47.
• [21]Lidauvais JC, Hwang ES, Karliner L, Nápoles A, Stewart S, Bloom J, Kaplan CP: Adjuvant hormonal therapy use among women with ductal carcinoma in situ. J Womens Health (Larchmt) 2012, 21(1):35-42. Epub 2011 Sep 8
• [22]Zujewski JA, Harlan LC, Morrell DM, Stevens JL: Ductal carcinoma in situ: trends in treatment over time in the US. Breast Cancer Res Treat 2011, 127(1):251-257.
• [23]Lee MG, Wynder C, Schmidt DM, McCafferty DG, Shiekhattar R: Histone H3 Lysine 4 Demethylation is a target of nonselective antidepressive medications. Chemistry and Biology 2006, 13:563-567.
• [24]Sobin LH, Gospodarowicz MK, Wittekind C: UICC: TNM classification of malignant tumors. 7th edition. Wiley-Blackwell, Oxford; 2009.